Social News
Written by: Li Enci
2019-11-27 19:53
Last updated: 2019-11-27 19:53The Department of Health announced today (27th) that it agreed to allow suppliers to recall two over-the-counter gastric drug products from the market because the related products contain "N-nitrosodimethylamine (NDMA)", which may be a carcinogen. The suppliers involved include Youhua Pharmaceutical Co., Ltd. and Hecheng (Asia) Co., Ltd. A spokesman for the Department of Health said the affected products had been supplied to local private doctors, pharmacies and drugstores, and patients who were taking the products should consult their medical staff.
150 mg of Emtac 150 tablets supplied by Youhua Pharmaceutical Co., Ltd. and 150 mg of Ranitid 150 tablets supplied by Hecheng (Asia) Co., Ltd. were found to contain NDMA, which may be a carcinogen, after testing by the government laboratory. The Department of Health agreed today that the two licensed drug suppliers should take precautionary measures to voluntarily recall the affected products from the market. Both companies have set up hotlines to answer related enquiries: Youhua (2695 8587) and Hecheng (2544 1401).
Affected products were supplied to private doctors
According to the supplier's information, the affected products have been supplied to local private doctors, pharmacies and drug stores. A spokesman for the Department of Health said no reports of adverse reactions involving the products have been received and the recalls will be closely monitored. The spokesman added that patients who are taking the above products should consult their healthcare professionals for appropriate arrangements. There are other alternative medicines on the market for similar uses.
Since September 24, the Department of Health has agreed to recall a total of 23 ranitidine-containing products. The Department of Health was also informed that overseas drug regulators are assessing the safety impact of ranitidine-containing products found to contain impurities. The Department will closely monitor the development of the incident and the overseas drug regulatory authority will issue an updated safety assessment of the drug to consider any necessary follow-up actions.
5 more stomach medicines containing or may cause carcinogenic impurities
Department of Health announces recall of 6 ranitidine-containing gastric medicines for possible carcinogenic impurities NDMA
Stomach medicine Epadoren needs to be recalled
Stomach medicines found to contain or may cause carcinogenic impurities need to be collected within a week. A total of 10 stomach medicines are affected.
Department of Health Gastrointestinal Diseases